CROSSJECT Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025 Reinforcement of supply chain [with addition of a second fill-and-finish